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The Polymeal: a more natural, safer, and probably tastier
(than the Polypill) strategy to reduce cardiovascular
disease by more than 75%
Oscar H Franco, Luc Bonneux, Chris de Laet, Anna Peeters, Ewout W Steyerberg,
Johan P Mackenbach
Abstract
Objective Although the Polypill concept (proposed in
2003) is promising in terms of benefits for
cardiovascular risk management, the potential costs
and adverse effects are its main pitfalls. The objective
of this study was to identify a tastier and safer
alternative to the Polypill: the Polymeal.
Methods Data on the ingredients of the Polymeal
were taken from the literature. The evidence based
recipe included wine, fish, dark chocolate, fruits,
vegetables, garlic, and almonds. Data from the
Framingham heart study and the Framingham
offspring study were used to build life tables to model
the benefits of the Polymeal in the general population
from age 50, assuming multiplicative correlations.
Results Combining the ingredients of the Polymeal
would reduce cardiovascular disease events by 76%.
For men, taking the Polymeal daily represented an
increase in total life expectancy of 6.6 years, an
increase in life expectancy free from cardiovascular
disease of 9.0 years, and a decrease in life expectancy
with cardiovascular disease of 2.4 years. The
corresponding differences for women were 4.8, 8.1,
and 3.3 years.
Conclusion The Polymeal promises to be an effective,
non-pharmacological, safe, cheap, and tasty
alternative to reduce cardiovascular morbidity and
increase life expectancy in the general population.
Introduction
Cardiovascular disease continues to be the leading
cause of mortality and morbidity in Western
populations.1 Although several risk factors for cardio-
vascular disease have been identified, its prevention is
still suboptimal owing to high costs, low compliance,
and side effects of treatment. In 2003 Wald and Law
introduced the concept of the Polypill.2 The advocates
of the Polypill selected six pharmacological compo-
nents that by modifying different risk factors of
cardiovascular disease multiplicatively might reduce
the levels of cardiovascular disease in the population
by more than 80%.2 In general, the medical
community has welcomed the concept but questioned
the potential adverse effects and costs of such an
intervention.
Our objective was to define a safer, non-
pharmacological, and tastier alternative to the Polypill
in the general population: the Polymeal. We also
wanted to calculate the potential effects of the
Polymeal in terms of total life expectancy and life
expectancy with and without cardiovascular disease.
Methods
The recipe
To optimise the Polymeal ingredients we used an
evidence based diet conceptual framework, which
follows similar principles to evidence based medicine.4
The constituting elements of a meal or recipe are
selected on the basis of the best available evidence; the
evidence available for each ingredient is graded
according to the level of evidence. We searched
PubMed, informed by expert advice, for non-
pharmacological ingredients with evidence levels 1 or
2: randomised controlled trials, meta-analyses of
randomised controlled trials, and meta-analyses of
observational studies.5 To be included in the Polymeal,
the ingredient had to have individually reported effects
(not as an element of a diet) on reduction in cardio-
vascular disease events or modification of risk factors
for cardiovascular disease. We checked papers
retrieved for further possible ingredients. The follow-
ing dietary elements met the inclusion criteria to be
ingredients of the Polymeal: wine, fish, dark chocolate,
fruits and vegetables, almonds, and garlic (Allium
sativum).
Efficacy of the Polymeal
We obtained information from the literature on the
benefits of the interventions (table 1). Daily consump-
tion of 150 ml of wine reduces cardiovascular disease
by 32% (95% confidence interval 33% to 41%).6 Fish
(114 g) consumed four times a week reduces
cardiovascular disease by 14% (8% to 19%).7 For
chocolate, fruits and vegetables, almonds, and garlic, we
found data on modification of risk factors for
cardiovascular disease. One hundred grams of dark
chocolate consumed daily reduces systolic blood pres-
sure by 5.1 mm Hg and diastolic blood pressure by 1.8
mm Hg8; similar reductions in blood pressure
correspond to a reduction in cardiovascular disease
events of 21% (14% to 27%).9 A total of 400 g of fruit
and vegetables consumed daily produced a reduction
in blood pressure similar to that observed with choco-
late (4.0 mm Hg systolic blood pressure and 1.5 mm
Hg diastolic blood pressure), so we decided to assume
Table 1 Effect of ingredients of Polymeal in reducing risk of cardiovascular disease
Ingredients
Percentage reduction
(95% CI) in risk of CVD Source
Wine (150 ml/day) 32 (23 to 41) Di Castelnuovo et al (MA)6
Fish (114 g four times/week) 14 (8 to 19) Whelton et al (MA)7
Dark chocolate (100 g/day) 21 (14 to 27) Taubert et al (RCT)8
Fruit and vegetables (400 g/day) 21 (14 to 27) John et al (RCT)10
Garlic (2.7 g/day) 25 (21 to 27) Ackermann et al (MA)11
Almonds (68 g/day) 12.5 (10.5 to 13.5) Jenkins et al (RCT),15 Sabate et al (RCT)16
Combined effect 76 (63 to 84)
CVD=cardiovascular disease; MA=meta-analysis; RCT=randomised controlled trial.
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the same reduction in cardiovascular disease effect as
assigned for chocolate (21%).10
Daily consumption of garlic reduced total choles-
terol concentrations by 0.44 mmol/l (17.1 mg/dl),11 12
corresponding to 66% of the reduction (0.66 mmol/l)
that was found to be associated with a 38% reduction in
cardiovascular disease at age 50.13 Therefore, we
considered 66% of the effect previously reported and
assumed a reduction of 25% (21.7% to 27.7%) in
cardiovascular disease events for garlic. Most of the
randomised controlled trials included in the meta-
analysis used 600-900 mg/day of dried garlic powder
preparations, equivalent to 1.8-2.7 g/day of fresh
garlic.14 We selected 2.7 g/day of fresh garlic for the
Polymeal. Consuming 68 g/day of almonds produced
half the reduction in total cholesterol (10 mg/dl)
observed with garlic,15 16 so we assumed a reduction in
cardiovascular disease half the one assigned to garlic.
We calculated the combined effect of the ingredi-
ents of the evidence based diet Polymeal by
multiplying their correspondent relative risk estimates.
This is the same method that was used for the Polypill.2
Study population
We applied the effects of the Polymeal to a life table
built using the Framingham study population. The
original Framingham heart study cohort consisted of
5209 respondents (2336 men) residing in Framing-
ham, Massachusetts, between 1948 and 1951. Partici-
pants have been examined biannually, and the cohort
has been followed for 46 years.17
We used follow up data from participants attending
study examinations 4 (1956-8), 11 if present or
otherwise 12 (1969-73), and 19 if present or otherwise
20 (1985-9). Follow up started at the date of the chosen
baseline examination. Each participant could therefore
be included more than once but for different follow up
periods of no more than 12 years in order to avoid
overlapping periods. A total of 9181 participant-
observation periods of follow up were available for the
analysis.
We used three endpoints in this study: the compos-
ite endpoint of incident non-fatal cardiovascular
disease (angina, coronary insufficiency, myocardial
infarction, congestive heart failure, stroke, transient
ischaemic attack, and intermittent claudication), fatal
cardiovascular disease, and other causes of death. In
the Framingham heart study, a panel of three
physicians evaluated all events (fatal and non-fatal);
agreement of all three was needed.18 We selected total
cardiovascular disease as the outcome (and not
coronary heart disease and stroke separated) on the
basis of current recommendations in the European
guidelines on cardiovascular disease prevention.19
Effects of the Polymeal on life expectancy and time
with cardiovascular disease
To translate the effects of the Polymeal on reduction of
cardiovascular disease events (table 1) in terms of
differences in life expectancy and life expectancy with
and without cardiovascular disease, we created
multi-state life tables starting at age 50 years and clos-
ing at 100 years of age. We stratified the multi-state life
tables by sex and created them separately for the gen-
eral population with and without the Polymeal. The
multi-state life tables included three different states:
“free from cardiovascular disease,” “history of cardio-
vascular disease,” and “death.” The possible transitions
were from “free from cardiovascular disease” to
“history of cardiovascular disease” or “death” and from
“history of cardiovascular disease” to “death.”20 In the
life tables representing the population with the
Polymeal, we derived the effects by decreasing the rates
for the transitions “free from cardiovascular disease” to
“history of cardiovascular disease” and “history of car-
diovascular disease” to “death” by the estimated risk
reduction associated with the Polymeal. We used Excel
spreadsheets for all analyses.
Results
Effects of the Polymeal
Combining all the ingredients of the Polymeal resulted
in cardiovascular disease being reduced by 76% (95%
confidence interval 63% to 84%) (table 1). Whether
increasing the amount of each ingredient would
increase the effect of the Polymeal is uncertain. On the
other hand, decreasing the quantities could be
expected to reduce the effects of the Polymeal.
Omitting wine from the Polymeal had the strongest
effect on the risk reduction of cardiovascular disease
(from 76% to 65%). Excluding any of the other
ingredients had a lesser effect: 73% reduction without
fish, 70% without chocolate or fruits and vegetables,
68% without garlic, and 73% without almonds.
Lifetime effects of the Polymeal
The effect of the Polymeal represented a large increase
in total life expectancy and life expectancy free from
cardiovascular disease and a decrease in life expect-
ancy with cardiovascular disease for both men and
women (table 2). For men, taking the Polymeal would
result in increases of 6.6 years in total life expectancy
and 9.0 years in life expectancy free from cardiovascu-
lar disease. The decrease in life expectancy with
cardiovascular disease attributable to the Polymeal was
2.4 years. The reductions were similar for women,
although the magnitudes were lower (table 2).
Adverse effects
No proved serious adverse effects were reported in any
of the papers selected. For garlic, in addition to body
odour, some unproved adverse effects were men-
tioned: flatulence, oesophageal and abdominal pain,
allergic reactions, and bleeding.11 Fish consumed in
larger amounts than recommended as part of the
Polymeal has been related to raised blood mercury
concentrations, especially with large fish such as shark
and swordfish.7 No association between wine con-
sumption at the level included in the Polymeal and
increased risk of breast cancer was reported by the
authors of the papers included in our analyses.6
Table 2 Lifetime effect (years) of Polymeal at age 50, stratified by sex
Intervention
Total life expectancy
Life expectancy
free from CVD Life expectancy with CVD
Effect Difference Effect Difference Effect Difference
Men:
None (overall) 28.7 Ref 21.0 Ref 7.7 Ref
Polymeal 35.2 6.6 30.0 9.0 5.3 −2.4
Women:
None (overall) 34.2 Ref 26.9 Ref 7.3 Ref
Polymeal 39.0 4.8 35.0 8.1 4.0 −3.3
CVD=cardiovascular disease; Ref=reference value.
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Discussion
The Polymeal is an effective, natural, probably safer,
and tastier alternative to the Polypill to reduce cardio-
vascular disease and increase life expectancy in the
general population. The effect was consistent in both
men and women at age 50. Adverse effects reported for
garlic include malodorous breath and body odour.13 As
garlic is destined for mass treatment, few people will
still notice this after a while. No additional adverse
effects should be expected from the other ingredients
of the Polymeal (in the quantities recommended here)
except in people who are allergic to the components.
Another advantage of the Polymeal is that its
ingredients can be taken combined as a meal or
individually at different times of the day. Taking the
Polymeal on a daily basis (fish two to four times a week)
should be feasible, considering that the ingredients are
generally well tolerated and appreciated among the
general population. The development and distribution
of specific recipes combining the Polymeal ingredients
could enhance the compliance of the population.
Costs and precautions
Although the exact price of the Polymeal is unknown
and will be country specific, it could be expected to be
similar to or perhaps higher than that of the Polypill.
By checking a local supermarket in Rotterdam, the
Netherlands, we estimated a total price for the
Polymeal of €21.60 (£15.20; $28.10) a week (€3.50 for
the wine, €6.23 for fruit and vegetables, €2.80 for
almonds, €4.34 for dark chocolate, €0.14 for garlic, and
€4.60 for fish). Although we do not recommend
particular brands, spending more—for example, on
your favourite bottle of wine or brand of chocolate—
might also be rewarded by an improved quality of life.
The Polymeal should not be combined with
additional consumption of alcohol, in order to avoid
intoxication and conflicts with friends, relatives, and
authorities; furthermore, additional alcohol consump-
tion could attenuate the effects of the Polymeal and
negatively influence other health measures. Driving
motor vehicles or performing activities that require
high levels of attention shortly after the consumption
of the Polymeal should be avoided. Moreover,
considering the disturbing adverse effects of garlic, we
do not recommend taking the Polymeal before a
romantic rendezvous, unless the partner also complies
with the Polymeal.
We believe our search was comprehensive and
although we looked for additional ingredients to
include in the Polymeal, we found no other potential
components with a sufficient level of evidence or with
clearly reported effects on cardiovascular disease
events or on modification of risk factors of cardiovas-
cular disease. Some other ingredients could be added
to the Polymeal (olive oil, echium oil, soya oil, soya
beans, tomatoes, oat bran, cereals, nuts, tea, chickpeas,
and so on), but this will only improve its effect on car-
diovascular disease risk reduction.
Concerns might be raised about the validity of the
source evidence and the multiplicative model used to
calculate effects of the ingredients of the Polymeal.
However, these are shared by the Polypill analyses, as
we used a similar approach. None the less, a greater
possibility of interaction exists between dietary factors
as less information is available about underlying
mechanisms of action. This might result in an overesti-
mation of the effect of the Polymeal.
Another potential limitation of our study is that no
back flows are allowed in the multi-state life tables, and
only the first entry into a state is considered. This is not
always seen in real patterns of morbidity and mortality.
No contraindications to combining the Polymeal
with additional interventions seem to exist. After the
daily consumption of the Polymeal, for example, half
an hour of walking could prevent further cardiovascu-
lar disease events.21 For those people earnestly seeking
to prevent cardiovascular disease, the Polypill can be
combined with the Polymeal. The fortification of flour
with Polypill ingredients (a statin, two antihypertensive
drugs instead of three, folic acid, and aspirin) certainly
merits further study. Redundant cardiologists could be
retrained as Polymeal chefs and wine advisers.
Conclusions
The preventive strategy outlined here is radical. But the
“healthy person” is an outdated concept from the era
before scientific prevention. We should recognise that
in Western society we all have cardiovascular risk
factors, so everyone is at risk, and the diseases they
cause are common and often fatal. It may be argued
that the Polypill is even more effective, but the
Polymeal promises to be an effective, non-
pharmacological, safe, and tasty alternative for
reducing cardiovascular morbidity and increasing life
expectancy in the general population.
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What is already known on this topic
Prevention of cardiovascular disease is limited by
high costs and low compliance
The concept of a combination pill (the Polypill) to
reduce cardiovascular disease by more than 80%
was introduced in 2003
Pharmacological interventions are not the only
option for preventing heart disease; a healthy diet
and an active lifestyle reduce cardiovascular
disease as well
What this study adds
A combined meal of seven food components (the
Polymeal) could reduce cardiovascular disease by
more than 75%
Chocolate, wine, fish, nuts, garlic, fruit, and
vegetables are all known to have a positive effect
on cardiovascular disease, and have been enjoyed
by humankind for centuries
Finding happiness in a frugal, active lifestyle can
spare us a future of pills and hypochondria
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Randomised controlled trial of magnetic bracelets for
relieving pain in osteoarthritis of the hip and knee
Tim Harlow, Colin Greaves, Adrian White, Liz Brown, Anna Hart, Edzard Ernst
Abstract
Objective To determine the effectiveness of
commercially available magnetic bracelets for pain
control in osteoarthritis of the hip and knee.
Design Randomised, placebo controlled trial with
three parallel groups.
Setting Five rural general practices.
Participants 194 men and women aged 45-80 years
with osteoarthritis of the hip or knee.
Intervention Wearing a standard strength static
bipolar magnetic bracelet, a weak magnetic bracelet,
or a non-magnetic (dummy) bracelet for 12 weeks.
Main outcome measures Change in the Western
Ontario and McMaster Universities osteoarthritis
lower limb pain scale (WOMAC A) after 12 weeks,
with the primary comparison between the standard
and dummy groups. Secondary outcomes included
changes in WOMAC B and C scales and a visual
analogue scale for pain.
Results Mean pain scores were reduced more in the
standard magnet group than in the dummy group
(mean difference 1.3 points, 95% confidence interval
0.05 to 2.55). Self reported blinding status did not
affect the results. The scores for secondary outcome
measures were consistent with the WOMAC A scores.
Conclusion Pain from osteoarthritis of the hip and
knee decreases when wearing magnetic bracelets. It is
uncertain whether this response is due to specific or
non-specific (placebo) effects.
Manufacturers of permanent static magnet devices
claim that they reduce pain in various conditions,
including osteoarthritis.1 Worldwide sales were esti-
mated at $5bn (£2.6bn, €3.8bn) in 1999.2 Osteoarthritis
affects around 760 000 people in the United Kingdom,
producing an estimated 3.02 million general practice
consultations in 2000.3 If magnets were effective they
would offer a cheap and probably safe treatment option.
Some studies of permanent static magnets have
found significant pain reduction2 4–9 whereas others
reported no effect.10–12 Major differences exist in the
type and strength of magnets used, the conditions
A chart showing flow of participants is on bmj.com
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